BioPharma Resources

Investigational drug · Phase 3

Serplulimab

Also called: HLX10, HLX43

Not approved by FDA. In 25 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

25

25 still active

All registered trials

156

Any phase or sponsor naming "Serplulimab"

First trial start

2020

Apr 17, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Serplulimab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non Small Cell Lung Cancer
  • Carcinoma, Hepatocellular
  • SCLC, Extensive Stage
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Triple Negative Breast Cancer
  • NSCLC Stage IV
  • Breast Cancer (Triple Negative Breast Cancer (TNBC))
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • Colon Cancer Adenocarcinoma
  • Hormone Receptor Positive HER-2 Negative Breast Cancer

Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Serplulimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 151 on PubMed

Also in development for Non Small Cell Lung Cancer

  • ZimberelimabAB122, GS-0122Phase 312 trials

    Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer

  • YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials

    MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer

  • DomvanalimabAB154, GS-0154Phase 310 trials

    Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer

  • SI-B001Phase 39 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck

  • TucidinostatChidamide, HBI-8000Phase 39 trials

    Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis

  • LBL-007AlcestobartPhase 38 trials

    BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer

  • aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials

    Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)

  • ONC-392Gotistobart, BNT316Phase 35 trials

    OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.